Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
516.69
-2.95 (-0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Argenx Se ADR
< Previous
1
2
3
Next >
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
July 25, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024
From
argenx SE
Via
GlobeNewswire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
July 16, 2024
From
argenx SE
Via
GlobeNewswire
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
July 16, 2024
From
Zai Lab Limited
Via
Business Wire
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
June 25, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
June 21, 2024
From
argenx SE
Via
GlobeNewswire
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
June 17, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
argenx SE
Via
GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
May 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 02, 2024
From
argenx SE
Via
GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024
From
argenx SE
Via
GlobeNewswire
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
February 20, 2024
From
argenx SE
Via
GlobeNewswire
5 medical stocks growing earnings by triple digits
February 06, 2024
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Via
MarketBeat
Topics
Economy
Exposures
Economy
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
January 18, 2024
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2024 Strategic Priorities
January 08, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
December 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
November 28, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
November 16, 2023
From
argenx SE
Via
GlobeNewswire
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 01, 2023
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.